PRINCETON, N.J., Oct. 25 /PRNewswire/ -- Laureate Pharma, Inc.
announced today that it has renewed its agreement with Cytogen Corporation
for the cGMP manufacture of ProstaScint(R), Cytogen's proprietary
monoclonal antibody immunoconjugate that is used for imaging in patients
diagnosed with prostate cancer. Under the agreement, Laureate will provide
cGMP protein production, purification, conjugation of Cytogen's proprietary
linker chelator and aseptic filling services to support Cytogen's
commercial ProstaScint(R) requirements. Terms of the agreement were not
disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO )
"We are delighted by the confidence that Cytogen has shown in Laureate
by continuing to utilize our specialized experience in the manufacture of
ProstaScint(R)," said Robert J. Broeze, President & CEO of Laureate. "We
have developed a great working relationship with our colleagues at Cytogen
and we look forward to helping them achieve their manufacturing
objectives."
ProstaScint(R) has been manufactured in Laureate's cGMP manufacturing
facility in Princeton, NJ for more than 10 years.
About Laureate Pharma
Laureate Pharma, a full-service biopharmaceutical development and
protein production company, located in Princeton, NJ, offers superior
bioprocessing services that accelerate new products from development
through production. Laureate provides a wide range of specialized services
from process design and development to full-scale cGMP production,
purification, aseptic filling, testing, validation, analytical services and
regulatory support. Laureate is focused on two active segments of the
biopharmaceutical industry: monoclonal antibodies and recombinant protein
products. For more information, contact Michael Cavanaugh, Vice President
Sales, Marketing, and Business Development at (609) 919-3400, or
info@laureatepharma.com or visit http://www.laureatepharma.com. Laureate Pharma,
Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE)
(http://www.safeguard.com), which builds value in high-growth, revenue stage
information technology and life sciences businesses. Safeguard provides
growth capital as well as a range of strategic, operational and management
resources to its partner companies.
SOURCE Laureate Pharma, Inc.
back to top
Related links: http://www.laureatepharma.com http://www.safeguard.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO PRN Photo Desk, photodesk@prnewswire.com
CONTACT: Michael Cavanaugh, Vice President Sales, Marketing, and Business Development, Laureate Pharma, +1-609-919-3400, info@laureatepharma.com
|